CN114868890A - Multi-vitamin nutrient formula suitable for tumor patients - Google Patents
Multi-vitamin nutrient formula suitable for tumor patients Download PDFInfo
- Publication number
- CN114868890A CN114868890A CN202210303901.2A CN202210303901A CN114868890A CN 114868890 A CN114868890 A CN 114868890A CN 202210303901 A CN202210303901 A CN 202210303901A CN 114868890 A CN114868890 A CN 114868890A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- extract
- tumor
- tumor patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 87
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 26
- 229940088594 vitamin Drugs 0.000 title claims abstract description 16
- 239000011782 vitamin Substances 0.000 title claims abstract description 16
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000000843 powder Substances 0.000 claims abstract description 36
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 24
- 239000003094 microcapsule Substances 0.000 claims abstract description 24
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 20
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 20
- 229940046009 vitamin E Drugs 0.000 claims abstract description 20
- 239000011709 vitamin E Substances 0.000 claims abstract description 20
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 17
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 17
- 235000021119 whey protein Nutrition 0.000 claims abstract description 17
- 102000008186 Collagen Human genes 0.000 claims abstract description 16
- 108010035532 Collagen Proteins 0.000 claims abstract description 16
- 229920001436 collagen Polymers 0.000 claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 15
- 235000021323 fish oil Nutrition 0.000 claims abstract description 14
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 13
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 12
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 12
- 239000004395 L-leucine Substances 0.000 claims abstract description 12
- 235000019454 L-leucine Nutrition 0.000 claims abstract description 12
- 229960003136 leucine Drugs 0.000 claims abstract description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 32
- 239000000284 extract Substances 0.000 claims description 31
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 25
- 244000182216 Mimusops elengi Species 0.000 claims description 25
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 25
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 25
- 235000020710 ginseng extract Nutrition 0.000 claims description 22
- 238000000855 fermentation Methods 0.000 claims description 17
- 230000004151 fermentation Effects 0.000 claims description 17
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 16
- 229930003268 Vitamin C Natural products 0.000 claims description 16
- 235000004879 dioscorea Nutrition 0.000 claims description 16
- 235000019154 vitamin C Nutrition 0.000 claims description 16
- 239000011718 vitamin C Substances 0.000 claims description 16
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 15
- 244000241838 Lycium barbarum Species 0.000 claims description 14
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 14
- 229930003316 Vitamin D Natural products 0.000 claims description 14
- 235000019166 vitamin D Nutrition 0.000 claims description 14
- 239000011710 vitamin D Substances 0.000 claims description 14
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 14
- 229940046008 vitamin d Drugs 0.000 claims description 14
- 235000008434 ginseng Nutrition 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 235000015468 Lycium chinense Nutrition 0.000 claims description 12
- 235000018102 proteins Nutrition 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 11
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 11
- 239000004222 ferrous gluconate Substances 0.000 claims description 11
- 235000013924 ferrous gluconate Nutrition 0.000 claims description 11
- 229960001645 ferrous gluconate Drugs 0.000 claims description 11
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 11
- 229930003231 vitamin Natural products 0.000 claims description 11
- 235000013343 vitamin Nutrition 0.000 claims description 11
- 239000011670 zinc gluconate Substances 0.000 claims description 11
- 235000011478 zinc gluconate Nutrition 0.000 claims description 11
- 229960000306 zinc gluconate Drugs 0.000 claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 8
- 229910052711 selenium Inorganic materials 0.000 claims description 8
- 239000011669 selenium Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 102000008114 Selenoproteins Human genes 0.000 claims description 5
- 108010074686 Selenoproteins Proteins 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 241000208340 Araliaceae Species 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 231100000357 carcinogen Toxicity 0.000 abstract description 7
- 239000003183 carcinogenic agent Substances 0.000 abstract description 7
- 210000000170 cell membrane Anatomy 0.000 abstract description 4
- 210000004072 lung Anatomy 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 210000000496 pancreas Anatomy 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 210000003932 urinary bladder Anatomy 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 description 31
- 230000000694 effects Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 16
- 230000036039 immunity Effects 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 14
- 230000006907 apoptotic process Effects 0.000 description 13
- 240000004371 Panax ginseng Species 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 238000002512 chemotherapy Methods 0.000 description 11
- 150000004676 glycans Chemical class 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 239000011573 trace mineral Substances 0.000 description 10
- 235000013619 trace mineral Nutrition 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 230000000711 cancerogenic effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229920001202 Inulin Polymers 0.000 description 7
- 235000013325 dietary fiber Nutrition 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 7
- 229940029339 inulin Drugs 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 206010005003 Bladder cancer Diseases 0.000 description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000004101 esophageal cancer Diseases 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 201000005112 urinary bladder cancer Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 231100000315 carcinogenic Toxicity 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 229910052732 germanium Inorganic materials 0.000 description 3
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 235000002722 Dioscorea batatas Nutrition 0.000 description 2
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 description 2
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000009982 effect on human Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 101150024147 bax gene Proteins 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- -1 compound vitamin Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000021540 dietary phytochemicals Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 1
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 201000004637 gastric cardia carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108700021654 myb Genes Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000007371 visceral function Effects 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a multi-vitamin nutrient formula suitable for tumor patients, which comprises the following raw materials in parts by weight: 1.5-1.6 parts of yam powder, 2.7-2.9 parts of hydrolyzed whey protein, 1-2 parts of collagen peptide, 1-2 parts of soybean protein, 0.0011-0.0013 part of L-glutamine, 0.0011-0.0013 part of L-leucine, 1.162-1.164 parts of medium-chain triglyceride microcapsule powder and 0.4-0.6 part of fish oil microcapsule powder. The vitamin E can act with oxygen free radicals to protect cell membrane lipid from being oxidized; epidemiological studies have observed that people with low levels of vitamin E in serum are more likely to develop tumors of the stomach, bladder, lung, pancreas, etc.; animal experiments show that vitamin E can inhibit the occurrence risk of tumors of various organs caused by carcinogens.
Description
Technical Field
The invention relates to the technical field of tumor patients, in particular to a multi-dimensional nutrient formula suitable for the tumor patients.
Background
The tumor is a pathological product formed by self or external multi-factor induction, while the holistic concept of the traditional Chinese medicine embodies unique advantages in the treatment process of the tumor, the traditional Chinese medicine treatment on the tumor directly acts on tumor cells, and more particularly, the regulation on the internal and external environments of a body comprises the tumor microenvironment. Meanwhile, the random control test result of the population shows that the compound vitamin and mineral preparation can obviously reduce the total death of the test population by 9 percent, the total cancer death by 13 percent, the stomach cancer death by 21 percent and the non-gastric cardia cancer death by 41 percent. Forest county nutritional intervention test results showed that intervention resulted in a reduction in total mortality, total cancer mortality, gastric and esophageal cancer mortality, with the baseline age of the subjects before 55 years of age being significantly more effective than after 55 years of age.
By reducing the intake of carcinogens and carcinogen precursors, the consumption of protective food is increased, the balanced diet is maintained, the physical activity is enhanced, the immunity of the organism is improved, and the purpose of diet cancer prevention can be achieved. Nutrients and dietary phytochemicals used as dietary supplements or fortified foods are often used as important means for maintaining and improving health, preventing and controlling the development of chronic diseases including cancer due to their safe, low toxicity, antioxidant effects. The invention provides a multi-dimensional nutrient formula suitable for tumor patients based on the fact that nutrition support treatment is necessary when chemotherapy is carried out on the elderly malignant tumor patients, nutrition intervention must be started as early as possible, the whole life process is continued, and the effect can be achieved constantly.
Disclosure of Invention
The invention aims to provide a multi-dimensional nutrient formula suitable for tumor patients to solve the problems in the background technology.
In order to achieve the purpose, the invention provides the following technical scheme:
a multi-vitamin nutrient formula suitable for tumor patients comprises the following raw materials in parts by weight:
1.5-1.6 parts of yam powder, 2.7-2.9 parts of hydrolyzed whey protein, 1-2 parts of collagen peptide, 1-2 parts of soybean protein, 0.0011-0.0013 part of L-glutamine, 0.0011-0.0013 part of L-leucine, 1.162-1.164 parts of medium-chain triglyceride microcapsule powder, 0.4-0.6 part of fish oil microcapsule powder, 0.001-0.003 part of vitamin D30.000044-0.000046 part of vitamin E, 0.012-0.014 part of vitamin C, 0.01-0.03 part of ferrous gluconate, 0.007-0.009 part of zinc gluconate, 0.007-0.009 part of selenium protein, 1-2 parts of ginseng extract and 1-2 parts of medlar extract.
Preferably, the formula of the multi-dimensional nutrient suitable for the tumor patients comprises the following raw materials in parts by weight:
1.55-1.6 parts of yam powder, 2.72-2.9 parts of hydrolyzed whey protein, 1.2-2 parts of collagen peptide, 1.2-2 parts of soybean protein, 0.0012-0.0013 part of L-glutamine, 0.0012-0.0013 part of L-leucine, 1.163-1.164 parts of medium-chain triglyceride microcapsule powder, 0.5-0.6 part of fish oil microcapsule powder, 0. 30.000045-0.000046 part of vitamin D, 0.002-0.003 part of vitamin E, 0.013-0.014 part of vitamin C, 0.02-0.03 part of ferrous gluconate, 0.008-0.009 part of zinc gluconate, 0.008-0.009 part of selenium protein, 1.2-2 parts of ginseng extract and 1.2-2 parts of wolfberry extract.
Preferably, the formula of the multi-dimensional nutrient suitable for the tumor patients comprises the following raw materials in parts by weight:
1.55 parts of yam powder, 2.8 parts of hydrolyzed whey protein, 1.5 parts of collagen peptide, 1.5 parts of soybean protein, 0.0012 part of L-glutamine, 0.0012 part of L-leucine, 1.163 parts of medium-chain triglyceride microcapsule powder, 0.5 part of fish oil microcapsule powder, 30.000045 parts of vitamin D, 0.002 part of vitamin E, 0.013 part of vitamin C, 0.02 part of ferrous gluconate, 0.008 part of zinc gluconate, 0.008 part of selenoprotein, 1.5 parts of ginseng extract and 1.5 parts of medlar extract.
Preferably, the Ginseng radix extract and fructus Lycii extract are prepared by fermenting, standing at 45-55 deg.C for 10-20min to obtain fermentation liquid, filtering to obtain extract,
Preferably, yeast is added in the fermentation, and the adding amount of the yeast is 1-5% of the total amount of the ginseng extract and the wolfberry extract.
Preferably, the yeast is added in an amount of 4% of the total amount of the ginseng extract and the wolfberry extract.
Preferably, the stirring speed in the fermentation is 400-500 r/min.
Preferably, the stirring speed is 500 r/min.
The product has the effects of regulating internal environment, and regulating body constitution.
Rhizoma Dioscoreae has effects of enhancing immunity, and synergistic effects of polysaccharide, saponin and microelement
The yam can be 'relaxed, not hungry and prolong life' from the Shennong Ben Cao Jing, has rich nutrient components, and has obvious effects of resisting tumors, enhancing immunoregulation and resisting mutation, such as yam polysaccharide, steroid saponin, trace elements and the like.
The Chinese yam polysaccharide can promote thymus-dependent lymphocyte proliferation caused by concanavalin A, can obviously improve the IL-2 generating capacity of spleen cells and TNF-alpha generating capacity of abdominal macrophages of mice with tumor while improving the T lymphocyte proliferation capacity and NK cell activity of mice with tumor, and can obviously enhance the tumor-related immune function of the mice. In addition, the yam polysaccharide can obviously increase the total number of peripheral blood leukocytes of mice which are inhibited by cyclophosphamide, and the yam medicinal materials can be used as adjuvant treatment medicines for antitumor drugs and chemotherapy. [4] Research shows that dioscin in yam can inhibit the proliferation of various tumor cells and induce them to apoptosis, such as breast cancer, bone and flesh cancer, colon cancer, leukemia and liver cancer; the action mechanism of the compound plays an anti-tumor role through immune regulation and is related to the suppression of the expression of cell-met, HGF/SF, myb genes and CDK4 genes. [5] The Chinese yam also contains various trace elements and vitamins, including trace elements of calcium, iron, zinc, selenium, chromium and 16 vitamins, and has rich content and relatively low heat content. Related health food or cancer treatment adjuvants have been developed in Taiwan of China to reduce the side effects caused by cancer chemotherapy or immunotherapy.
Ginseng radix for treating tumor and regulating immune system
Ginseng is the dry root of Panax ginseng C.A.Meyer of Araliaceae, cultivated is radix Ginseng Indici, and wild is radix Ginseng Indici. The record of Shen nong Ben Cao records that Ginseng, sweet in taste and slightly cold in nature, tonifies five internal organs, calms spirit, makes soul, stops palpitation, removes pathogenic factors, improves eyesight, opens heart and benefits intelligence. It can be taken for a long time, and has effects of reducing weight and prolonging life. One in the mouth, one in the lid, raw valley ". The ginseng is a best product for nourishing yin, tonifying life and strengthening body resistance from ancient praise, and the modern pharmacological research shows that the ginseng has the effects of resisting tumors, improving memory, resisting aging, improving immunity, improving heart and cerebral vessels and the like.
The therapeutic effects of supporting healthy energy on tumors include the regulation of immune cells such as T lymphocytes, natural killer cells NK, dendritic cells DC and the like in TME. Ginseng is a representative tonifying drug and widely used in clinic, and has the main effects of tonifying qi, strengthening body resistance and activating human immune system. The main components of Ginseng radix are ginsenoside and panaxan, and the ginsenoside includes Rg1, Rg3, Rb1, CK, etc. A large number of documents report that ginsenoside can inhibit tumor cell proliferation and angiogenesis, promote tumor cell apoptosis, regulate immunity, reverse drug resistance of tumor cells and the like; the panaxan mainly comprises panaxan starch and panaxan pectin, and can stimulate various immune cells of organism to regulate its immunological activity, restore balance of immune system, induce tumor cell apoptosis, and inhibit tumor infiltration and metastasis.
The polysaccharide, flavone and microelement in fructus Lycii have immunity enhancing, antitumor, and other effects
Medlar tonifies kidney and benefits essence, nourishes liver and improves eyesight, enriches blood and tranquilizes mind, promotes fluid production and quenches thirst. Modern researches show that the medlar has obvious inhibition effect on human cancer cells, and the medlar has obvious inhibition effect on human gastric adenocarcinoma KATO-DI cells and human cervical carcinoma Hela cells; the tumor weight inhibition rate of wolfberry on the mouse S180 solid tumor is 42%. The fructus Lycii extractive solution has inhibitory effect on carcinogen-induced mutation, with inhibition rates of 91.8% and 82.6%. Moreover, the medlar has obvious radiation synergistic effect by combining radiotherapy and chemotherapy, and has great significance as an auxiliary medicament for tumor chemotherapy. The medlar can reduce the harm of the chemotherapeutic drug to the body and improve the tumor treatment capacity of the chemotherapeutic drug, for example, medlar polysaccharide has obvious synergistic effect on the cancer treatment of paclitaxel, the medlar polysaccharide and fluorouracil can be combined to increase the reduction of spleen index caused by the single application of fluorouracil, and the reduction of the proliferation reaction of spleen lymphocytes caused by the single application of fluorouracil is improved. Moreover, the medlar can effectively inhibit the growth and the metastasis of tumors by inhibiting the formation of tumor blood vessels.
The medlar is taken for a long time as a tonifying medicine, has no obvious toxic or side effect, has more anticancer effect as a biological response regulator, and plays a role in assisting in treating the cancer by improving the immunity of the organism, enhancing the sensitivity of cancer cells to radiotherapy, chemotherapy and immunity and increasing the tolerance of a host to cytotoxic chemotherapy. In addition, the scientific research of western countries discovers that the medlar contains mineral trace element germanium/124 ppm, the germanium is an anticancer molecule, and the content of the germanium and the like in the medlar is 28 times of that of rice and 3 times of that of Korean ginseng.
The polysaccharide substances in the medlar are also very interesting, and some of the medlar are even higher in tumor inhibition rate than that of a broad-spectrum anticancer drug cyclophosphamide, so that the medlar is an active ingredient which is very worthy of research and development. Lycium barbarum polysaccharides can induce tumor cell apoptosis by regulating cell cycle regulatory factor, intracellular apoptosis signal pathway, apoptosis inhibiting gene, destroying cell membrane surface structure, etc. The inhibition rate can reach more than 60 percent, obviously inhibits the expression of cell cycle regulatory factors cyclin D, cyclin E and CDK2, and blocks cells in the G0/G1 stage. In addition, the lycium barbarum polysaccharide can obviously reduce the tumor volume of a liver cancer mouse, inhibit the growth of cancer cells and reduce the activity of telomerase of a liver cancer tissue, thereby achieving the purpose of inhibiting the growth of liver cancer. Moreover, the efficacy of the drug combination with the chemotherapeutic drug is better than that of the drug combination used alone, and the anti-tumor efficacy of the lycium barbarum polysaccharide is exerted to the maximum extent.
Except polysaccharide components, the fructus Lycii flavone can promote Caspase-3 expression in breast cancer MCF-7 cells and reduce Bcl-2 expression (P < 0.05). The suggestion is that the lycium barbarum flavone can inhibit the proliferation of breast cancer MCF-7 cells and promote the apoptosis of the breast cancer MCF-7 cells.
Rhizoma Polygonati can stimulate and enhance immunity, and can be used for treating various tumors
Rhizoma Polygonati has effects of invigorating qi, nourishing yin, invigorating spleen, moistening lung, and invigorating kidney. Has the functions of stimulating and enhancing immunity, delaying senility, resisting virus and the like, has obvious curative effect on treating various tumors such as bladder cancer, esophageal cancer and the like, and can be used for treating adverse reactions such as bone marrow suppression, oral ulcer and the like caused by chemotherapy. For example, patients with bladder cancer often use adriamycin for bladder perfusion to reduce the recurrence probability, and rhizoma Polygonati can prevent and treat cardiotoxicity caused by adriamycin.
Clinically, sealwort is mainly used for treating bladder cancer, lung cancer, breast cancer, prostate cancer, esophageal cancer, cardiac cancer, gastric cancer, intestinal cancer and other digestive tract tumors and is indicated for patients with spleen and kidney deficiency or yin deficiency and fire excess. Sealwort can not only obviously inhibit the growth of in vitro H22 transplanted tumor, stop cells in G0/G1 stage to block cell proliferation, improve the activity of Caspase-3,8 and 9 in tumor tissues and accelerate the apoptosis of tumor cells, but also reduce the number of in vivo Heps and Eca tumor cells, and the action mechanism of the sealwort can accelerate the apoptosis of tumor cells by stopping the tumor cells in S stage.
The nutritional supplement can significantly increase the antitumor effect of the drug, maintain the organ function, and reduce the incidence of complications and side effects (i.e., the intake of high-quality protein (whey protein and collagen peptide) should be increased for patients with malignant tumor
The nutritional status of malignant tumor patients significantly affects the growth of the tumor, and is closely related to prognosis. Protein metabolism disorders are a significant manifestation of patients with malignant tumors. Amino acids, as protein synthesis raw materials and breakdown products, are also significantly altered in cancer patients. The synthesis and decomposition of protein of cancer patients are increased, but the decomposition rate is higher than the synthesis rate, so the protein of the body is reduced, and the protein level of plasma is reduced. Insufficient protein intake increases protein consumption in the body, leading to skeletal muscle consumption. Therefore, cancer patients should be supplemented with protein and amino acids in time to correct the negative nitrogen balance in vivo.
Whey protein is extracted from milk by modern production process, and the content of whey protein in milk is only 0.7%, which is called king of protein. Whey protein is a recognized high-quality protein supplement for humans: easy digestion and high bioavailability; the branched chain amino acid is rich, and can be used as an energy source substance to provide energy; is a good source of sulfur-containing amino acids such as cysteine, methionine and the like, can maintain the level of Glutathione (GSH) in vivo and plays a role in oxidation resistance; contains a large amount of lysine and arginine, and can stimulate the secretion of anabolic hormone and promote muscle growth; is a good source of calcium with high bioavailability, and can prevent osteoporosis; and the research finds that the whey protein has the anticancer effect.
The collagen peptide has a remarkable inhibiting effect on tumors under the condition of specific molecular weight. This result is an important finding in the field of human cancer and has been patented in countries such as the united states. Improving the immunity of human body and strengthening the function of internal organs; the immunity of human body is related to the biological molecules of immunoglobulin, and after the immune cells are combined with collagen, the immune system of human body can increase over one hundred times of immunity to resist foreign matters. In addition, the collagen is an important nutrient source, contains rich amino acid, is frequently supplemented in a proper amount, and is beneficial to strengthening the functions of various tissues and organs and improving the immunity of a human body. Such as increasing cell proliferation, strengthening visceral function, protecting liver, promoting insulin secretion, promoting milk secretion, relieving constipation, inhibiting cancer cell metastasis, and preventing aging.
The soybean protein peptide is a pure natural nutrient substance extracted from soybeans and is also an important component of human cells. Mainly consists of 2-10 amino acids, and the molecular weight is below 3000. Plays an extremely important role in life activities, and has the effects of improving immunity, enhancing physical strength, relieving fatigue, reducing high blood pressure, high blood sugar, high blood fat and high blood sugar and the like for postoperative convalescent patients, tumor patients, patients with radiotherapy and chemotherapy, patients with poor gastrointestinal functions and the like.
The (di) omega-3 unsaturated fatty acid can remarkably reduce inflammatory reaction of malignant tumor patients
Abnormal lipid metabolism in cancer patients is characterized by increased fat mobilization, decreased lipid synthesis, increased fatty acid synthesis, and decreased lipoprotein lipase activity. Thus, for patients with advanced cancer who are undergoing chemotherapy and are at risk for weight loss or malnutrition, omega-3 long chain fatty acids or fish oil can be supplemented to stabilize or improve appetite, food intake, and body weight. DHA and EPA can increase the flexibility of cell membranes, increase the activity of immune cells, and facilitate the information transmission of the immune cells and the killing of tumor cells; EPA and DHA also have anti-inflammatory activity, and when the human body takes too much omega-6-fatty acid (which is usually contained in a large amount in vegetable oil) and the omega-3-fatty acid is insufficient, the body can generate some chemical substances to cause inflammatory reaction, while EPA and DHA can balance the too much omega-6-fatty acid, so fish oil is often used for improving various inflammations, including inflammatory infiltration of tumors and the like.
Inulin (dietary fiber) can improve intestinal function of malignant tumor patients, promote prognosis, and prevent and treat tumor
Inulin (dietary fiber) not only has the characteristics of absorbing and preserving water, but also can combine with harmful and carcinogenic substances in intestinal tract and promote the discharge of the harmful and carcinogenic substances, and promote the decomposition of the carcinogenic substances. Inulin (dietary fiber) can also promote the growth of probiotics, inhibit the growth of pathogenic bacteria, thereby inhibiting the generation of carcinogen, and promote the intestinal decomposition; and simultaneously, the phagocytic capacity of the giant thia cells can be improved, the synthesis of nitrosamine can be blocked, and the estrogen level can be reduced. In addition, the inulin (dietary fiber) can also generate short-chain fatty acid in colon by bacterial glycolysis, and research proves that the short-chain fatty acid is closely related to tumorigenesis development, and can regulate (promote) apoptosis in positive phase and play a role in preventing tumorigenesis by inhibiting the expression of apoptosis inhibiting gene Bcl-2 and apoptosis promoting Bax gene in cells. The current research has more abundant evidence that high inulin (dietary fiber) intake can reduce the risk of tumor onset, the total inulin (dietary fiber) intake is inversely related to the tumor onset, and the increase of inulin (dietary fiber) intake is a protective factor of tumor.
And (IV) the trace elements such as zinc, iron and the like which are lost in vivo are supplemented, so that the immune function of a patient with malignant tumor can be obviously enhanced.
The relationship between the action of trace elements and malignant tumors has become the focus and target of extensive research by experts and scholars in recent years. The change of the content of the trace elements in the body is closely related to the generation, development and treatment of tumors, and has important application value for the diagnosis, curative effect and prognosis observation of malignant tumors. The decrease of serum zinc, selenium and iron and the increase of copper and copper/zinc ratio of tumor patients are well known and closely related to and negatively related to the morbidity and mortality of gastric cancer and esophageal cancer of human beings. Therefore, supplementing corresponding trace elements according to the requirements has an important effect on enhancing the immune function of the tumor patients and really improving the survival quality of the tumor patients.
Vitamin C, D, E can correct metabolic abnormality of malignant tumor patients and reduce adverse reaction of radiotherapy and chemotherapy.
The data published by the american cancer society in 2012 states that the daily requirements of vitamins and trace elements for cancer patients approach the physiological requirements of normal individuals, and thus the daily recommended intake of vitamins and trace elements for normal individuals.
Research shows that the vitamin-containing medicine can reduce adverse reaction of radiotherapy and chemotherapy after combined operation. The water-soluble vitamin for injection is used as a kind of intravenous nutrition to supplement the physiological needs of various water-soluble vitamins every day, so that various related biochemical reactions of the organism can be normally carried out. The normal cells of human body can be cancerated under the action of carcinogenic factors, but the early cancerated cells can also be reversed into normal cells under the action of certain factors. Cyclic adenosine monophosphate (cAMP) is needed in the reversion process, vitamin C is a coenzyme for manufacturing the cyclic adenosine monophosphate, vitamin C is sufficient in a human body, the cyclic adenosine monophosphate is sufficient, and the anticancer capability is strong. Vitamin C acts as a prodrug delivered to tissues by H2O2 to selectively kill tumor cells, and Padayatty et al report that large doses of vitamin C administered intravenously to patients with advanced renal, bladder and lymphoma tumors can cause regression of the tumors in the patients.
Vitamin D is a fat-soluble steroid derivative, most commonly vitamin D2 and vitamin D3. The biological effect of vitamin D is mainly exerted by binding with its receptor, and has antitumor effect, and the main antitumor mechanism includes inhibiting tumor cell proliferation, promoting apoptosis, regulating body's immunity, etc. With regard to the relationship between vitamin D and tumors, scholars at home and abroad develop a great deal of related population research, including the research on the relationship between vitamin D and more common malignant tumors such as colorectal cancer, breast cancer, prostate cancer and the like. Vitamin D levels in vivo are negatively correlated with the risk of developing colorectal, breast, lung, and bladder cancer; vitamin D intervention can also improve prognosis in patients with hematologic malignancies.
Compared with the prior art, the invention has the following beneficial effects:
the vitamin E can act with oxygen free radicals to protect cell membrane lipid from being oxidized; epidemiological studies have observed that people with low levels of vitamin E in serum are more likely to develop tumors of the stomach, bladder, lung, pancreas, etc.; animal experiments show that vitamin E can inhibit the occurrence of tumors of various organs caused by carcinogens, wherein the tumors comprise breast cancer, colon cancer, liver cancer and the like. Eating more vitamin E-containing food can improve immunity and inhibit carcinogen formation. A recent study in the united states also demonstrated that vitamin E has a protective effect against prostate and bladder cancer. Research shows that high concentration of vitamin E in blood can reduce the risk of gastric cancer and esophageal cancer.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below with reference to specific embodiments, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The multivitamin nutrient formula applicable to tumor patients comprises the following raw materials in parts by weight:
1.5-1.6 parts of yam powder, 2.7-2.9 parts of hydrolyzed whey protein, 1-2 parts of collagen peptide, 1-2 parts of soybean protein, 0.0011-0.0013 part of L-glutamine, 0.0011-0.0013 part of L-leucine, 1.162-1.164 parts of medium-chain triglyceride microcapsule powder, 0.4-0.6 part of fish oil microcapsule powder, 0.001-0.003 part of vitamin D30.000044-0.000046 part of vitamin E, 0.012-0.014 part of vitamin C, 0.01-0.03 part of ferrous gluconate, 0.007-0.009 part of zinc gluconate, 0.007-0.009 part of selenium protein, 1-2 parts of ginseng extract and 1-2 parts of medlar extract.
The formula of the multi-dimensional nutrient suitable for tumor patients comprises the following raw materials in parts by weight:
1.55-1.6 parts of yam powder, 2.72-2.9 parts of hydrolyzed whey protein, 1.2-2 parts of collagen peptide, 1.2-2 parts of soybean protein, 0.0012-0.0013 part of L-glutamine, 0.0012-0.0013 part of L-leucine, 1.163-1.164 parts of medium-chain triglyceride microcapsule powder, 0.5-0.6 part of fish oil microcapsule powder, 0. 30.000045-0.000046 part of vitamin D, 0.002-0.003 part of vitamin E, 0.013-0.014 part of vitamin C, 0.02-0.03 part of ferrous gluconate, 0.008-0.009 part of zinc gluconate, 0.008-0.009 part of selenium protein, 1.2-2 parts of ginseng extract and 1.2-2 parts of wolfberry extract.
The formula of the multi-dimensional nutrient suitable for tumor patients comprises the following raw materials in parts by weight:
1.55 parts of yam powder, 2.8 parts of hydrolyzed whey protein, 1.5 parts of collagen peptide, 1.5 parts of soybean protein, 0.0012 part of L-glutamine, 0.0012 part of L-leucine, 1.163 parts of medium-chain triglyceride microcapsule powder, 0.5 part of fish oil microcapsule powder, 30.000045 parts of vitamin D, 0.002 part of vitamin E, 0.013 part of vitamin C, 0.02 part of ferrous gluconate, 0.008 part of zinc gluconate, 0.008 part of selenoprotein, 1.5 parts of ginseng extract and 1.5 parts of medlar extract.
The ginseng extract and the medlar extract are extracted and fermented in a fermentation mode, are placed at 45-55 ℃ for 10-20min to obtain fermentation liquor, and are filtered to obtain the extract,
In the fermentation of this example, yeast is added in an amount of 1-5% of the total amount of the ginseng extract and the wolfberry extract.
The yeast in this example is added in an amount of 4% of the total amount of the ginseng extract and the wolfberry extract.
The stirring speed in the fermentation of the embodiment is 400-500 r/min.
The stirring speed in this example was 500 r/min.
Example 1:
the multivitamin nutrient formula applicable to tumor patients comprises the following raw materials in parts by weight:
1.5 parts of yam powder, 2.7 parts of hydrolyzed whey protein, 1 part of collagen peptide, 1 part of soybean protein, 0.0011 part of L-glutamine, 0.0011 part of L-leucine, 1.162 part of medium-chain triglyceride microcapsule powder, 0.4 part of fish oil microcapsule powder, 30.000044 parts of vitamin D, 0.001 part of vitamin E, 0.012 part of vitamin C, 0.01 part of ferrous gluconate, 0.007 part of zinc gluconate, 0.007 part of selenoprotein, 1 part of ginseng extract and 1 part of medlar extract.
The ginseng extract and the medlar extract of the embodiment are extracted and fermented by a fermentation mode, are placed at 45 ℃ for 10min to obtain fermentation liquor, and are filtered to obtain the extract,
In the fermentation of this example, yeast was added in an amount of 1% of the total amount of the ginseng extract and the wolfberry extract.
The stirring speed in the fermentation of this example was 400 r/min.
Example 2:
the multivitamin nutrient formula applicable to tumor patients comprises the following raw materials in parts by weight:
1.55 parts of yam powder, 2.8 parts of hydrolyzed whey protein, 1.5 parts of collagen peptide, 1.5 parts of soybean protein, 0.0012 part of L-glutamine, 0.0012 part of L-leucine, 1.163 parts of medium-chain triglyceride microcapsule powder, 0.5 part of fish oil microcapsule powder, 30.000045 parts of vitamin D, 0.002 part of vitamin E, 0.013 part of vitamin C, 0.02 part of ferrous gluconate, 0.008 part of zinc gluconate, 0.008 part of selenoprotein, 1.5 parts of ginseng extract and 1.5 parts of medlar extract.
The ginseng extract and the medlar extract are extracted and fermented in a fermentation mode, are placed at 45-55 ℃ for 10-20min to obtain fermentation liquor, and are filtered to obtain the extract,
The yeast in this example is added in an amount of 4% of the total amount of the ginseng extract and the wolfberry extract.
The stirring speed in this example was 500 r/min.
It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative embodiments, and that the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Furthermore, it should be understood that although the present specification describes embodiments, not every embodiment includes only a single embodiment, and such description is for clarity purposes only, and it is to be understood that all embodiments may be combined as appropriate by one of ordinary skill in the art to form other embodiments as will be apparent to those of skill in the art from the description herein.
Claims (8)
1. The multi-vitamin nutrient formula applicable to tumor patients is characterized by comprising the following raw materials in parts by weight:
1.5-1.6 parts of yam powder, 2.7-2.9 parts of hydrolyzed whey protein, 1-2 parts of collagen peptide, 1-2 parts of soybean protein, 0.0011-0.0013 part of L-glutamine, 0.0011-0.0013 part of L-leucine, 1.162-1.164 parts of medium-chain triglyceride microcapsule powder, 0.4-0.6 part of fish oil microcapsule powder, 0.001-0.003 part of vitamin D30.000044-0.000046 part of vitamin E, 0.012-0.014 part of vitamin C, 0.01-0.03 part of ferrous gluconate, 0.007-0.009 part of zinc gluconate, 0.007-0.009 part of selenium protein, 1-2 parts of ginseng extract and 1-2 parts of medlar extract.
2. The multi-dimensional nutrient formula suitable for tumor patients according to claim 1, which comprises the following raw materials in parts by weight:
1.55-1.6 parts of yam powder, 2.72-2.9 parts of hydrolyzed whey protein, 1.2-2 parts of collagen peptide, 1.2-2 parts of soybean protein, 0.0012-0.0013 part of L-glutamine, 0.0012-0.0013 part of L-leucine, 1.163-1.164 parts of medium-chain triglyceride microcapsule powder, 0.5-0.6 part of fish oil microcapsule powder, 0. 30.000045-0.000046 part of vitamin D, 0.002-0.003 part of vitamin E, 0.013-0.014 part of vitamin C, 0.02-0.03 part of ferrous gluconate, 0.008-0.009 part of zinc gluconate, 0.008-0.009 part of selenium protein, 1.2-2 parts of ginseng extract and 1.2-2 parts of wolfberry extract.
3. The multi-dimensional nutrient formula suitable for tumor patients according to claim 1, which comprises the following raw materials in parts by weight:
1.55 parts of yam powder, 2.8 parts of hydrolyzed whey protein, 1.5 parts of collagen peptide, 1.5 parts of soybean protein, 0.0012 part of L-glutamine, 0.0012 part of L-leucine, 1.163 parts of medium-chain triglyceride microcapsule powder, 0.5 part of fish oil microcapsule powder, 30.000045 parts of vitamin D, 0.002 part of vitamin E, 0.013 part of vitamin C, 0.02 part of ferrous gluconate, 0.008 part of zinc gluconate, 0.008 part of selenoprotein, 1.5 parts of ginseng extract and 1.5 parts of medlar extract.
4. The multi-dimensional nutrient formula for patients with tumor as claimed in claim 1, wherein the Ginseng radix extract and fructus Lycii extract are prepared by extracting and fermenting in fermentation mode, standing at 45-55 deg.C for 10-20min to obtain fermentation liquid, and filtering to obtain extract.
5. The multi-dimensional nutrient formula suitable for tumor patients as claimed in claim 4, wherein yeast is added during the fermentation, and the addition amount of yeast is 1-5% of the total amount of the ginseng extract and the wolfberry extract.
6. The multi-dimensional nutrient formula suitable for tumor patients as claimed in claim 5, wherein the addition amount of yeast is 4% of the total amount of the ginseng extract and the wolfberry extract.
7. The multi-dimensional nutrient formula suitable for tumor patients as claimed in claim 5, wherein the stirring speed in the fermentation is 400-500 r/min.
8. The multi-dimensional nutrient formula for tumor patients as claimed in claim 7, wherein the stirring speed is 500 r/min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210303901.2A CN114868890A (en) | 2022-03-26 | 2022-03-26 | Multi-vitamin nutrient formula suitable for tumor patients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210303901.2A CN114868890A (en) | 2022-03-26 | 2022-03-26 | Multi-vitamin nutrient formula suitable for tumor patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114868890A true CN114868890A (en) | 2022-08-09 |
Family
ID=82667996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210303901.2A Pending CN114868890A (en) | 2022-03-26 | 2022-03-26 | Multi-vitamin nutrient formula suitable for tumor patients |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114868890A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115989872A (en) * | 2022-12-07 | 2023-04-21 | 山东欣希安药业股份有限公司 | Composition for improving nutritional status of tumor patient and preparation method thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101496579A (en) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | Special diet and foodstuffs formula containing small peptide for tumor patient |
| CN104207139A (en) * | 2014-07-28 | 2014-12-17 | 胡安然 | Total-nutritional formulation food used for tumor |
| CN105296313A (en) * | 2015-12-02 | 2016-02-03 | 青岛浩大海洋保健食品有限公司 | Compound and fermented ginseng health drink and production process thereof |
| CN108991500A (en) * | 2018-07-02 | 2018-12-14 | 邦世迪(广东)医用食品股份有限公司 | A kind of tumour patient full nutrition formula food |
| CN109744543A (en) * | 2019-01-09 | 2019-05-14 | 长沙市惠瑞生物科技有限公司 | A kind of bone collagen peptide composite powder and preparation method thereof |
| CN109938337A (en) * | 2019-04-10 | 2019-06-28 | 吉林省九圣源生物科技有限公司 | A kind of herbal cuisine eaten for malignant tumour peri-operation period crowd |
| CN110613793A (en) * | 2019-10-14 | 2019-12-27 | 福建省中医药研究院(福建省青草药开发服务中心） | Anti-tumor composition and preparation method and application thereof |
| CN111480839A (en) * | 2020-03-26 | 2020-08-04 | 上海复旦奥医医学科技有限公司 | Special clinical nutrition formula for bone cancer and preparation method thereof |
| CN111657488A (en) * | 2020-05-26 | 2020-09-15 | 颜如玉医药科技有限公司 | Fermented vegetable protein composite peptide nutritional composition and preparation method thereof |
| CN111938145A (en) * | 2020-07-20 | 2020-11-17 | 江苏省肿瘤医院 | Nutritional formula for patients with esophageal cancer |
| CN112089051A (en) * | 2019-12-04 | 2020-12-18 | 上海张新生物医药科技有限公司 | Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof |
-
2022
- 2022-03-26 CN CN202210303901.2A patent/CN114868890A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101496579A (en) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | Special diet and foodstuffs formula containing small peptide for tumor patient |
| CN104207139A (en) * | 2014-07-28 | 2014-12-17 | 胡安然 | Total-nutritional formulation food used for tumor |
| CN105296313A (en) * | 2015-12-02 | 2016-02-03 | 青岛浩大海洋保健食品有限公司 | Compound and fermented ginseng health drink and production process thereof |
| CN108991500A (en) * | 2018-07-02 | 2018-12-14 | 邦世迪(广东)医用食品股份有限公司 | A kind of tumour patient full nutrition formula food |
| CN109744543A (en) * | 2019-01-09 | 2019-05-14 | 长沙市惠瑞生物科技有限公司 | A kind of bone collagen peptide composite powder and preparation method thereof |
| CN109938337A (en) * | 2019-04-10 | 2019-06-28 | 吉林省九圣源生物科技有限公司 | A kind of herbal cuisine eaten for malignant tumour peri-operation period crowd |
| CN110613793A (en) * | 2019-10-14 | 2019-12-27 | 福建省中医药研究院(福建省青草药开发服务中心） | Anti-tumor composition and preparation method and application thereof |
| CN112089051A (en) * | 2019-12-04 | 2020-12-18 | 上海张新生物医药科技有限公司 | Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof |
| CN111480839A (en) * | 2020-03-26 | 2020-08-04 | 上海复旦奥医医学科技有限公司 | Special clinical nutrition formula for bone cancer and preparation method thereof |
| CN111657488A (en) * | 2020-05-26 | 2020-09-15 | 颜如玉医药科技有限公司 | Fermented vegetable protein composite peptide nutritional composition and preparation method thereof |
| CN111938145A (en) * | 2020-07-20 | 2020-11-17 | 江苏省肿瘤医院 | Nutritional formula for patients with esophageal cancer |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115989872A (en) * | 2022-12-07 | 2023-04-21 | 山东欣希安药业股份有限公司 | Composition for improving nutritional status of tumor patient and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101473953B (en) | Fabricated food for cleaning blood and expelling toxin as well as method for processing the same and application | |
| CN103238897A (en) | Composite plant solid drink suitable for diabetic patients | |
| CN102526445B (en) | Health-care medicament formula with functions of strengthening immunity, relieving physical fatigue and resisting tumor | |
| CN105815514A (en) | Weight-losing quinoa milk tea | |
| CN113575934A (en) | Total-nutrient compound protein powder for tumor patients | |
| CN105410932A (en) | Tumor immunity type nutritional composition and application thereof | |
| CN111436601A (en) | Special clinical nutrition formula for pancreatic cancer and preparation thereof | |
| CN107279978A (en) | A kind of special medicine purposes formula food suitable for tumour patient | |
| CN111771988A (en) | Nutritional food suitable for diabetic patients and preparation method thereof | |
| CN110754656A (en) | Special clinical nutrition formula for lymphoma function and preparation method thereof | |
| CN114868890A (en) | Multi-vitamin nutrient formula suitable for tumor patients | |
| CN112385843A (en) | Balanced nutrition powder containing composite prebiotics and preparation method thereof | |
| CN111374312A (en) | Health food for supplementing comprehensive nutrition and easy absorption | |
| CN108782679A (en) | A kind of weight-reducing intervention is dry and preparation method thereof for refreshment | |
| CN111802633A (en) | Special clinical nutrition formula for esophageal cancer and preparation method thereof | |
| CN110638038A (en) | Medical formula nutritional meal replacement powder for controlling hyperglycemia and preparation method thereof | |
| CN108371709A (en) | Lycium ruthenicum tumor recovering gene enzyme | |
| CN108887561A (en) | A kind of meal replacement powder formula with reducing blood lipid effect of lowering blood sugar | |
| CN113749152A (en) | Health preserving and body building drink and preparation method thereof | |
| CN106035686A (en) | Super chenopodium quinoa willd health-preservation plant milk | |
| CN112690386A (en) | A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity | |
| CN110050911A (en) | Five-cereal health-care dew | |
| CN111109490A (en) | Soybean lecithin solid beverage | |
| CN107259530A (en) | It is a kind of to be used to calm the nerves, improve the passion fruit formula food of sleep | |
| CN106418548A (en) | Health-care food formula capable of preventing and treating hypertension, hyperlipidemia and hyperglycemia and production process of health-care food formula |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |